Trials / Completed
CompletedNCT01615068
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,007 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.
Conditions
Timeline
- Start date
- 2012-06-05
- Primary completion
- 2017-11-16
- Completion
- 2017-11-16
- First posted
- 2012-06-08
- Last updated
- 2018-07-16
Locations
142 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01615068. Inclusion in this directory is not an endorsement.